These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 22900848

  • 21. Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.
    Sumida T, Kitadai Y, Shinagawa K, Tanaka M, Kodama M, Ohnishi M, Ohara E, Tanaka S, Yasui W, Chayama K.
    Int J Cancer; 2011 May 01; 128(9):2050-62. PubMed ID: 21387285
    [Abstract] [Full Text] [Related]

  • 22. Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB.
    Aoki M, Nabeshima K, Koga K, Hamasaki M, Suzumiya J, Tamura K, Iwasaki H.
    Lab Invest; 2007 Aug 01; 87(8):767-79. PubMed ID: 17558420
    [Abstract] [Full Text] [Related]

  • 23. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
    Razis E, Selviaridis P, Labropoulos S, Norris JL, Zhu MJ, Song DD, Kalebic T, Torrens M, Kalogera-Fountzila A, Karkavelas G, Karanastasi S, Fletcher JA, Fountzilas G.
    Clin Cancer Res; 2009 Oct 01; 15(19):6258-66. PubMed ID: 19789313
    [Abstract] [Full Text] [Related]

  • 24. Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
    George D.
    Semin Oncol; 2001 Oct 01; 28(5 Suppl 17):27-33. PubMed ID: 11740804
    [Abstract] [Full Text] [Related]

  • 25. Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma.
    Agnihotri S, Gugel I, Remke M, Bornemann A, Pantazis G, Mack SC, Shih D, Singh SK, Sabha N, Taylor MD, Tatagiba M, Zadeh G, Krischek B.
    J Neurosurg; 2014 Dec 01; 121(6):1434-45. PubMed ID: 25245477
    [Abstract] [Full Text] [Related]

  • 26. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor.
    Abouantoun TJ, MacDonald TJ.
    Mol Cancer Ther; 2009 May 01; 8(5):1137-47. PubMed ID: 19417143
    [Abstract] [Full Text] [Related]

  • 27. Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo.
    Kelly DJ, Cox AJ, Gow RM, Zhang Y, Kemp BE, Gilbert RE.
    Hypertension; 2004 Aug 01; 44(2):195-202. PubMed ID: 15197170
    [Abstract] [Full Text] [Related]

  • 28. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
    Sugiura H, Fujiwara Y, Ando M, Kawai A, Ogose A, Ozaki T, Yokoyama R, Hiruma T, Ishii T, Morioka H, Mugishima H.
    J Orthop Sci; 2010 Sep 01; 15(5):654-60. PubMed ID: 20953927
    [Abstract] [Full Text] [Related]

  • 29. Potential roles of growth factor PDGF-BB in the bony repair of injured growth plate.
    Chung R, Foster BK, Zannettino AC, Xian CJ.
    Bone; 2009 May 01; 44(5):878-85. PubMed ID: 19442606
    [Abstract] [Full Text] [Related]

  • 30. Vestibular Schwannoma Excision in Sporadic versus Neurofibromatosis Type 2 Populations.
    Mahboubi H, Maducdoc MM, Yau AY, Ziai K, Ghavami Y, Badran KW, Al-Thobaiti M, Brandon B, Djalilian HR.
    Otolaryngol Head Neck Surg; 2015 Nov 01; 153(5):822-31. PubMed ID: 25791708
    [Abstract] [Full Text] [Related]

  • 31. A chorioallantoic membrane model for the determination of anti-angiogenic effects of imatinib.
    Özcetin A, Aigner A, Bakowsky U.
    Eur J Pharm Biopharm; 2013 Nov 01; 85(3 Pt A):711-5. PubMed ID: 23891770
    [Abstract] [Full Text] [Related]

  • 32. Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas.
    Sirén V, Antinheimo JP, Jääskeläinen J, Böhling T, Carpén O, Vaheri A.
    Acta Neurochir (Wien); 2004 Feb 01; 146(2):111-8. PubMed ID: 14963743
    [Abstract] [Full Text] [Related]

  • 33. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation.
    Vlahovic G, Rabbani ZN, Herndon JE, Dewhirst MW, Vujaskovic Z.
    Br J Cancer; 2006 Oct 23; 95(8):1013-9. PubMed ID: 17003785
    [Abstract] [Full Text] [Related]

  • 34. Platelet-derived growth factor blockade on cardiac remodeling following infarction.
    Liu C, Zhao W, Meng W, Zhao T, Chen Y, Ahokas RA, Liu H, Sun Y.
    Mol Cell Biochem; 2014 Dec 23; 397(1-2):295-304. PubMed ID: 25148874
    [Abstract] [Full Text] [Related]

  • 35. Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials.
    George D.
    Adv Exp Med Biol; 2003 Dec 23; 532():141-51. PubMed ID: 12908555
    [Abstract] [Full Text] [Related]

  • 36. Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells.
    Yamaguchi SI, Ueki A, Sugihara E, Onishi N, Yaguchi T, Kawakami Y, Horiuchi K, Morioka H, Matsumoto M, Nakamura M, Muto A, Toyama Y, Saya H, Shimizu T.
    Cancer Sci; 2015 Jul 23; 106(7):875-82. PubMed ID: 25940371
    [Abstract] [Full Text] [Related]

  • 37. PDGF receptors as targets in tumor treatment.
    Ostman A, Heldin CH.
    Adv Cancer Res; 2007 Jul 23; 97():247-74. PubMed ID: 17419949
    [Abstract] [Full Text] [Related]

  • 38. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
    Bran B, Bran G, Hörmann K, Riedel F.
    Int J Oncol; 2009 Jan 23; 34(1):255-61. PubMed ID: 19082496
    [Abstract] [Full Text] [Related]

  • 39. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.
    Ammoun S, Schmid MC, Triner J, Manley P, Hanemann CO.
    Neuro Oncol; 2011 Jul 23; 13(7):759-66. PubMed ID: 21727212
    [Abstract] [Full Text] [Related]

  • 40. Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model.
    Jain RK, Lahdenranta J, Fukumura D.
    PLoS Med; 2008 Jan 29; 5(1):e24. PubMed ID: 18232729
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.